Pituitary and adrenal function in normal women after treatment with Lergotrile mesylate.
We studied the effects of a dopaminergic agonist, 2-chloro-6-methyl-ergoline-8-beta-acetonitrile methanesulfonate (LERGOTRILE mesylate), on the pituitary and adrenal function of five normal women. No changes were observed in basal serum luteinizing hormone (LH), follicle-stimulating hormone (FSH), growth hormone (GH) and cortisol levels, in LH and FSH levels after luteinizing hormone-releasing hormone (LH-RH) stimulation, or in GH and cortisol levels during insulin-induced hypoglycemia. Lergotrile treatment produced a fall in basal prolactin and thyrotropin (TSH) levels and there was dissociation in the responses of the women to thyrotropin-releasing hormone: attenuation of TSH release, but retention of prolactin release.
D000097:Acetonitriles / Q000494:pharmacology; D004873:Ergolines / Q000494:pharmacology*; D005260:Female; D006065:Gonadotropins, Pituitary / Q000097:blood; D013006:Growth Hormone / Q000097:blood; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D010908:Pituitary Hormones, Anterior / Q000097:blood*; D010913:Pituitary-Adrenal System / Q000187:drug effects / Q000502:physiology*; D013972:Thyrotropin / Q000097:blood; D013973:Thyrotropin-Releasing Hormone / Q000494:pharmacology
D000097:Acetonitriles; D004873:Ergolines; D006065:Gonadotropins, Pituitary; D010908:Pituitary Hormones, Anterior; D013973:Thyrotropin-Releasing Hormone; D013972:Thyrotropin; D013006:Growth Hormone; D006854:Hydrocortisone